Literature DB >> 7642848

Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators.

W J Rogers1, M G Bourassa, T C Andrews, B D Bertolet, R S Blumenthal, B R Chaitman, S A Forman, N L Geller, A D Goldberg, G B Habib.   

Abstract

OBJECTIVES: This report discusses the outcome at 1 year in patients in the Asymptomatic Cardiac Ischemia Pilot (ACIP) study.
BACKGROUND: Comparative efficacy of medical therapy versus revascularization in treatment of asymptomatic ischemia is unknown. The ACIP study assessed the ability of three treatment strategies to suppress ambulatory electrocardiographic (ECG) ischemia to determine whether a large-scale trial studying the impact of these strategies on clinical outcomes was feasible.
METHODS: Five hundred fifty-eight patients with coronary anatomy amenable to revascularization, at least one episode of asymptomatic ischemia on the 48-h ambulatory ECG and ischemia on treadmill exercise testing were randomized to one of three treatment strategies: 1) medication to suppress angina (angina-guided strategy, n = 183); 2) medication to suppress both angina and ambulatory ECG ischemia (ischemia-guided strategy, n = 183); or 3) revascularization strategy (angioplasty or bypass surgery, n = 192). Medication was titrated atenolol-nifedipine or diltiazem-isosorbide dinitrate.
RESULTS: The revascularization group received less medication and had less ischemia on serial ambulatory ECG recordings and exercise testing than those assigned to the medical strategies. The ischemia-guided group received more medication but had suppression of ischemia similar to the angina-guided group. At 1 year, the mortality rate was 4.4% in the angina-guided group (8 of 183), 1.6% in the ischemia-guided group (3 of 183) and 0% in the revascularization group (overall, p = 0.004; angina-guided vs. revascularization, p = 0.003; other pairwise comparisons, p = NS). Frequency of myocardial infarction, unstable angina, stroke and congestive heart failure was not significantly different among the three strategies. The revascularization group had significantly fewer hospital admissions and nonprotocol revascularizations at 1 year. The incidence of death, myocardial infarction, nonprotocol revascularization or hospital admissions at 1 year was 32% with the angina-guided medical strategy, 31% with the ischemia-guided medical strategy and 18% with the revascularization strategy (p = 0.003).
CONCLUSIONS: After 1 year, revascularization was superior to both angina-guided and ischemia-guided medical strategies in suppressing asymptomatic ischemia and was associated with better outcome. These findings require confirmation by a larger scale trial.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642848     DOI: 10.1016/0735-1097(95)00228-v

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

2.  Recognising "painless" heart attacks.

Authors:  C-K Wong; H D White
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

3.  Waiting lists for health care: a necessary evil?

Authors:  R F Davies
Journal:  CMAJ       Date:  1999-05-18       Impact factor: 8.262

Review 4.  ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques.

Authors:  Peter H Stone
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-04       Impact factor: 1.468

5.  The relationship between revascularization extent and the long-term prognosis of patients with stable angina pectoris and three-vessel disease treated by percutaneous coronary intervention in the era of drug-eluting stents.

Authors:  Quan Li; Xianpeng Yu; Jiqiang He; Yuechun Gao; Xiaoling Zhang; Changyan Wu; Yawei Luo; Yuchen Zhang; Xuejun Ren; Shuzheng Lv; Fang Chen
Journal:  Clin Cardiol       Date:  2014-08-14       Impact factor: 2.882

6.  Budget impact of applying appropriateness criteria for myocardial perfusion scintigraphy: The perspective of a developing country.

Authors:  Mauro Augusto Dos Santos; Marisa Silva Santos; Bernardo Rangel Tura; Renata Félix; Adriana Soares X Brito; Andrea De Lorenzo
Journal:  J Nucl Cardiol       Date:  2016-05-26       Impact factor: 5.952

Review 7.  [Significance of silent myocardial ischemia for identification and optimal therapy of patients with latent coronary heart disease. Is there a marker for prognostic indication for PTCA?].

Authors:  D Hering; H P Schultheiss; D Horstkotte
Journal:  Herz       Date:  1999-02       Impact factor: 1.443

Review 8.  Initial strategy of revascularization versus optimal medical therapy for improving outcomes in ischemic heart disease: a review of the literature.

Authors:  A Vincent Songco; Sorin J Brener
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

9.  Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials.

Authors:  H C Bucher; P Hengstler; C Schindler; G H Guyatt
Journal:  BMJ       Date:  2000-07-08

Review 10.  The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST-segment to evaluate ischemia: a review.

Authors:  Neil J Wimmer; Benjamin M Scirica; Peter H Stone
Journal:  Prog Cardiovasc Dis       Date:  2013-08-16       Impact factor: 8.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.